[Hyperfibrinolysis as the cause of so-called "spontaneous hemorrhages"].
D000614:Aminocaproates / Q000627:therapeutic use; D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D001565:Benzoates / Q000627:therapeutic use; D001778:Blood Coagulation Disorders / Q000188:drug therapy / Q000209:etiology*; D001780:Blood Coagulation Tests; D001791:Blood Platelet Disorders / Q000150:complications; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use; D005165:Factor V; D005166:Factor V Deficiency; D005169:Factor VIII; D005337:Fibrin / Q000378:metabolism; D005342:Fibrinolysis; D006386:Hemagglutination Tests; D006470:Hemorrhage / Q000188:drug therapy / Q000209:etiology*; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D005779:Immunodiffusion; D007122:Immunoelectrophoresis; D010958:Plasminogen / Q000037:antagonists & inhibitors; D013300:Streptokinase / Q000627:therapeutic use; D013921:Thrombocytopenia
D000614:Aminocaproates; D000933:Antifibrinolytic Agents; D001565:Benzoates; D003509:Cyclohexanecarboxylic Acids; D005165:Factor V; D005169:Factor VIII; D005337:Fibrin; D010958:Plasminogen; D006493:Heparin; D013300:Streptokinase
Hyperfibrinolyse als Ursache von sogenannten "Spontanblutungen".